Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

NCT00006226 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

NIH

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions

DRUG: thalidomide
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)